Payment overview · 2025
General Payments
$280.35
13 reported records · 9 companies
Healthcare provider profile · identity verified
Christopher Edge, D.O.
Allopathic & Osteopathic Physicians|General Practice · NORMAN, OK · NPI 1447233184
Verified facts
What the public records show
CMS Open Payments records show Christopher Edge, D.O. received $280.35 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.97 | 24.6% | 3 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $59.99 | 21.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.81 | 10.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.23 | 9.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.22 | 8.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.32 | 6.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.17 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.77 | 6.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.87 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $280.35 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 369 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 288 | 38 |
| Alprazolam | Alprazolam | 284 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 52 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 167 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 110 | 20 |
| Omeprazole | Omeprazole | 108 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 32 |
| Montelukast Sodium | Montelukast Sodium | 92 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 24 |
| Gabapentin | Gabapentin | 84 | 22 |
| Simvastatin | Simvastatin | 82 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 19 |
| Meloxicam | Meloxicam | 80 | 19 |
| Trazodone Hcl | Trazodone Hcl | 71 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 70 | suppressed |
| Temazepam | Temazepam | 69 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 13 |
| Azithromycin | Azithromycin | 67 | 51 |
| Clonazepam | Clonazepam | 67 | 14 |
| Pregabalin | Pregabalin | 65 | 13 |
| Lisinopril | Lisinopril | 64 | 19 |
| Valacyclovir | Valacyclovir Hcl | 60 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 57 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 16 |
| Carisoprodol | Carisoprodol | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 15 |
| Metformin Hcl | Metformin Hcl | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 50 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 12 |
| Estradiol | Estradiol | 41 | 15 |
| Diazepam | Diazepam | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Losartan Potassium | Losartan Potassium | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 18 |
| Torsemide | Torsemide | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | 11 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Dexamethasone | Dexamethasone | 35 | 28 |
| Prednisone | Prednisone | 35 | 14 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 33 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 11 |
| Valsartan | Valsartan | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 17 |
| Nicotrol Ns | Nicotine | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Linzess | Linaclotide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.35 · 13 records | Amgen Inc. | AIRSUPRA, Dexcom G6 Transmitter, JARDIANCE, NALOCET, NURTEC ODT, OTEZLA, PROLATE, REPATHA, SYNCHROMEDII, TANLOR, WATCHMAN FLX, YUPELRI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error